GTSM:4120

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs. More Details


Snowflake Analysis

Fair value with acceptable track record.

Share Price & News

How has Orient EuroPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4120 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4120's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-0.2%

4120

0.8%

TW Pharmaceuticals

1.2%

TW Market


1 Year Return

-11.6%

4120

38.7%

TW Pharmaceuticals

20.4%

TW Market

Return vs Industry: 4120 underperformed the TW Pharmaceuticals industry which returned 38.7% over the past year.

Return vs Market: 4120 underperformed the TW Market which returned 20.4% over the past year.


Shareholder returns

4120IndustryMarket
7 Day-0.2%0.8%1.2%
30 Day0.6%1.4%10.2%
90 Day-9.2%-9.4%9.6%
1 Year-8.4%-11.6%41.1%38.7%24.8%20.4%
3 Year-32.3%-38.9%48.0%40.0%45.1%29.0%
5 Year-7.9%-21.5%19.8%9.7%96.0%61.7%

Long-Term Price Volatility Vs. Market

How volatile is Orient EuroPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orient EuroPharma undervalued compared to its fair value and its price relative to the market?

16.4x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4120 (NT$50.3) is trading above our estimate of fair value (NT$40.92)

Significantly Below Fair Value: 4120 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4120 is good value based on its PE Ratio (16.4x) compared to the TW Pharmaceuticals industry average (17.3x).

PE vs Market: 4120 is good value based on its PE Ratio (16.4x) compared to the TW market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4120's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4120 is good value based on its PB Ratio (1.3x) compared to the TW Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is Orient EuroPharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

39.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orient EuroPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Orient EuroPharma performed over the past 5 years?

-5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4120 has high quality earnings.

Growing Profit Margin: 4120's current net profit margins (4.7%) are higher than last year (3.9%).


Past Earnings Growth Analysis

Earnings Trend: 4120's earnings have declined by 5.8% per year over the past 5 years.

Accelerating Growth: 4120's earnings growth over the past year (14%) exceeds its 5-year average (-5.8% per year).

Earnings vs Industry: 4120 earnings growth over the past year (14%) underperformed the Pharmaceuticals industry 23.1%.


Return on Equity

High ROE: 4120's Return on Equity (4.4%) is considered low.


Next Steps

Financial Health

How is Orient EuroPharma's financial position?


Financial Position Analysis

Short Term Liabilities: 4120's short term assets (NT$4.3B) exceed its short term liabilities (NT$2.2B).

Long Term Liabilities: 4120's short term assets (NT$4.3B) exceed its long term liabilities (NT$1.8B).


Debt to Equity History and Analysis

Debt Level: 4120's debt to equity ratio (50.5%) is considered high.

Reducing Debt: 4120's debt to equity ratio has increased from 26.5% to 50.5% over the past 5 years.

Debt Coverage: 4120's debt is not well covered by operating cash flow (17.8%).

Interest Coverage: 4120's interest payments on its debt are well covered by EBIT (18x coverage).


Balance Sheet


Next Steps

Dividend

What is Orient EuroPharma current dividend yield, its reliability and sustainability?

3.58%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4120's dividend (3.58%) is higher than the bottom 25% of dividend payers in the TW market (2.11%).

High Dividend: 4120's dividend (3.58%) is low compared to the top 25% of dividend payers in the TW market (5.17%).


Stability and Growth of Payments

Stable Dividend: 4120's dividend payments have been volatile in the past 10 years.

Growing Dividend: 4120's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (58.7%), 4120's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Peter Tsai

no data

Tenure

Mr. Peter Tsai has been the President and Chief Executive Officer of Orient Europharma Co., Ltd. Mr. Tsai serves as the Chairman of Orient Pharma Co., Ltd. and Orient Europharma Co. Ltd. Mr. Tsai studied f...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Orient EuroPharma Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orient EuroPharma Co., Ltd.
  • Ticker: 4120
  • Exchange: GTSM
  • Founded: 1982
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$4.363b
  • Shares outstanding: 86.75m
  • Website: https://www.oepgroup.com/zh-TW

Location

  • Orient EuroPharma Co., Ltd.
  • No. 368, Fu Hsing South Road
  • 7th Floor
  • Taipei
  • 106
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4120GTSM (Taipei Exchange)YesCommon StockTWTWDNov 2003

Biography

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs. The company offers prescription medicines for cardiovascular, immunology, metabolism, neurology, gynecology, respirat...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/30 08:34
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.